Exploiting Epigenetic Alterations in Prostate Cancer.
Exploiting Epigenetic Alterations in Prostate Cancer.
复制标题
DOI：
10.3390/ijms18051017
复制
发表时间：
2017-05-09
影响因子：
5.6
通讯作者：
Haendler B
中科院分区：
文献类型：
--
作者：
Baumgart SJ;Haendler B
前列腺癌影响全球越来越多的男性，是癌症相关死亡的主要原因。除了基因突变之外，在临床前列腺肿瘤样品中已经鉴定出许多表观遗传改变，包括DNA和组蛋白修饰。它们与参与这些表观遗传过程的酶和阅读器蛋白的异常活性有关，从而导致寻找专用的抑制化合物。在临床前模型中令人鼓舞的抗肿瘤疗效结果之后，针对不同靶点的表观遗传调节剂现在正在前列腺癌患者中进行测试。此外，正在讨论microRNA作为分层生物标志物的评估，以及评估抑制microRNA作为潜在前列腺癌治疗的早期临床试验。
Prostate cancer affects an increasing number of men worldwide and is a leading cause of cancer-associated deaths. Beside genetic mutations, many epigenetic alterations including DNA and histone modifications have been identified in clinical prostate tumor samples. They have been linked to aberrant activity of enzymes and reader proteins involved in these epigenetic processes, leading to the search for dedicated inhibitory compounds. In the wake of encouraging anti-tumor efficacy results in preclinical models, epigenetic modulators addressing different targets are now being tested in prostate cancer patients. In addition, the assessment of microRNAs as stratification biomarkers, and early clinical trials evaluating suppressor microRNAs as potential prostate cancer treatment are being discussed.